HealthyPhase 1NCT01819922
Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters
A Phase 1 study testing PF-05175157 in people with Healthy, run by Pfizer at 1 site in United States.
Trial summary
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- PF-05175157
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2013to Oct 2013
- Phase
- Phase 1
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male and/or female subjects of non child bearing potential only, between the ages of 18 and 40 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
- Body Mass Index (BMI) of 18 to 28 kg/m2; and a total body weight >50 kg (110 lbs).
- Subjects with maximum effort studies (peak RER >1.05) and normal exercise capacity as defined by peak VO2 ≥80% and ≤120% of predicted and no evidence of inducible ischemia or significant arrhythmia at the time of peak aerobic capacity testing 3 (±1) days prior to initiation of the study.
Who cannot join
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- History of smoking in the past 5 years or history or evidence of habitual use of other (non smoked) tobacco or nicotine-containing products within 3 months of Screening or positive cotinine test at Screening or Day -3 (±1).
- Dry eye symptoms
Trial locations and contacts
1 site in 1 country.
United States1 site
Massachusetts General Hospital
Boston, Massachusetts, 02114
About this study
Official title: A Phase 1 Randomized, Double-blind, Placebo-controlled, Two-way Crossover Study To Assess The Effect Of Pf-05175157 As A Single Oral Dose On Metabolic And Cardiopulmonary Parameters During Steady State And Graded Exercise In Healthy Subjects
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.
- Conditions
- Healthy
- Being tested
- PF-05175157, Placebo
- Keywords
- Cardiopulmonary exercise testing, metabolic parameters, Diabetes Mellitus Type 2
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PF-05175157Drug
600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
PlaceboDrug
Placebo powder in capsule, one dose within 5 minutes prior to AM meal
| Study group | Role | What they receive |
|---|---|---|
| PF-05175157 | Experimental | Not described Receives: Drug: PF-05175157 |
| Placebo | Placebo comparator | Not described Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 20 Minutes Pre-dose
Global longitudinal left ventricular strain was defined as the percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global longitudinal LV strain was assessed by echocardiography using speckled tracking analysis.
Measured: 20 minutes pre-dose
Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 1 Hour 30 Minutes Post-dose
Global longitudinal left ventricular strain was defined as the percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global longitudinal LV strain was assessed by echocardiography using speckled tracking analysis.
Measured: 1 hour 30 minutes post-dose
Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 2 Hours 5 Minutes Post-dose
Global longitudinal left ventricular strain was defined as the percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global longitudinal LV strain was assessed by echocardiography using speckled tracking analysis.
Measured: 2 hours 5 minutes post-dose
Cardiopulmonary Exercise Test: Oxygen Uptake Efficiency Slope (OUES): 1 Hour 40 Minute Post-dose
OUES was defined as an index of cardiopulmonary functional reserve that was based upon a submaximal exercise effort. OUES relates oxygen uptake to total ventilation during exercise.
Measured: 1 hour 40 minutes post-dose
Secondary outcomes (36)
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly; or a medically important event. Treatment-emergent were events between first dose of study drug and up to 5-10 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. Adverse events included both serious and non-serious adverse events.
Measured: Baseline up to 5-10 days after last dose of study drug (up to 25 days)
Number of Participants With Clinically Significant Laboratory Abnormalities
Criteria for clinically significant:Hematology (hemoglobin,hematocrit,red blood corpuscles [RBC] count:less than [<]0.8*lower limit of normal [LLN];platelets:<0.5*LLN/greater than [>]1.75*upper limit of normal [ULN];white blood corpuscles [WBC]:<0.6*LLN or >1.5*ULN;lymphocytes, total neutrophils:<0.8*LLN or >1.2*ULN;basophils,eosinophil, monocytes:>1.2*ULN);Liver Function(aspartate aminotransferase, alanine aminotransferase,alkaline phosphatase:>0.3*ULN;total protein,albumin:<0.8*LLN or >1.2*ULN;total bilirubin:>1.5*ULN);Renal Function (blood urea nitrogen,creatinine:>1.3*ULN; uric acid:>1.2*ULN);Electrolytes (sodium:<0.95*LLN or >1.05*ULN,potassium,chloride, calcium,bicarbonate:<0.9*LLN or >1.1*ULN; glucose fasting:<0.6*LLN or >1.5*ULN);Urinalysis (urine pH:>1.5*ULN or >4.5;urine glucose,ketones,proteins, nitrites, leukocyte esterase,blood/hemoglobin:greater than or equal to (>=)1;urine WBC and RBC,urine bacteria:>=20/High Power Field [HPF];epithelial cells:>=6/HPF).
Measured: Baseline up-to 3 hours post-dose
Number of Participants With Categorical Post-dose Cardiovascular Monitoring Data
Participants who met the pre-defined criteria for clinically significant cardiovascular events were reported. Criteria for clinically significant cardiovascular events: Blood pressure (BP) [supine systolic and sitting systolic BP (SBP): <90 millimeter of mercury (mm Hg), >=30 mmHg maximum increase and decrease from baseline in same posture; supine diastolic and sitting diastolic BP (DBP): <50 mm Hg, >=20 mmHg maximum increase and >=30 mmHg maximum decrease from baseline in same posture]; pulse rate: supine and sitting: <40 or >120 bpm.
Measured: Baseline up-to 3 hours post-dose
Number of Participants With Categorical Post-dose Cardiovascular Monitoring Data: Electrocardiogram (ECG) Parameters
Criteria for clinically significant ECG values included: maximum PR interval >=300 millisecond (msec) and maximum increase of >=25 percent (%) from baseline value of >200 msec and >=50 % for baseline value of <=200 msec, maximum QRS interval >=140 msec or maximum increase of >=50% for baseline value of >100 msec; QT interval corrected using the Fridericia formula (QTcF) 450-<480 msec, 480-<500, >=500 msec or increase of >45 msec or maximum increase of >=30 to <60 and >=60 msec for QT interval where, PR interval: interval between the start of the P wave and the start of the QRS complex corresponding to the time between the onset of atrial depolarization and onset of ventricular depolarization; QRS interval: time from electrocardiogram Q wave to the end of the T wave corresponding to ventricle depolarization, QTcF interval: time corresponding to the beginning of depolarization to repolarization of the ventricles.
Measured: Baseline up-to 3 hour post-dose
Cardiopulmonary Exercise Test: Peak Volume of Oxygen (VO2)
VO2 was the maximum rate of oxygen consumption as measured during incremental or prolonged, sub-maximal exercise. It reflects the aerobic physical fitness of the individual. It was assessed during indirect measure of heat production (calorimetry). The unit of measure is milliliter per kilogram per minute (mL/kg/min).
Measured: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Respiratory Exchange Ratio (RER)
RER was defined as the ratio between the amount of oxygen (O2) consumed and carbon dioxide (CO2) produced in one breath. The parameter was assessed during indirect measure of heat production (calorimetry).
Measured: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)
VE/VCO2 slope was also termed as ventilator efficiency. It was defined as the amount of minute ventilation required to eliminate 1 liter of carbon dioxide. The determinants of VE/VCO2 included fractional dead space and partial pressure of carbon dioxide. The parameter was assessed during indirect calorimetry.
Measured: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Volume of Oxygen (VO2) at Anaerobic Threshold (AT)
VO2 at anaerobic threshold was widely recognized as a sub-max indicator of fitness. The parameter was assessed during indirect calorimetry.
Measured: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Oxygen (O2) Pulse
Oxygen Pulse (VO2 /Heart Rate) was equal to stroke volume multiplied by oxygen extraction. This parameter was assessed during cardiopulmonary exercise test.
Measured: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Oxygen (O2) Kinetics
Oxygen kinetics describes the dependence of respiration of isolated cells on oxygen partial pressure. The characteristics of oxygen uptake kinetics differ with intensity of exercise.
Measured: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Aerobic Efficiency
Aerobic efficiency was defined as volume of oxygen divided by work. This parameter was assessed during cardiovascular exercise test.
Measured: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Physical Work Capacity at a Heart Rate of 130 Beats Per Minute (PWC 130)
Physical work capacity evaluates the capacity of an individual to perform physically demanding work tasks. PWC 130 was a simple sub-max exercise parameter that can be used as surrogate for fitness that was independent of metabolic cart measurements. Interventions that improve fitness improve the PWC 130.
Measured: 1 hour 40 minutes post-dose
Cardiac Structure: Left Ventricular Volume
Left ventricular volume was defined as volume of blood pumped from the left ventricle to the heart per beat. It was calculated using measurements of ventricle volumes from an echocardiogram and subtracting the volume of the blood in the ventricle at the end of a beat (called end-systolic volume) from the volume of blood just prior to the beat (called end-diastolic volume). Left ventricular volume was reported using modified Simpson's technique.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in the Left Ventricular Volume
Left ventricular volume was defined as volume of blood pumped from the left ventricle to the heart per beat. It was calculated using measurements of ventricle volumes from an echocardiogram and subtracting the volume of the blood in the ventricle at the end of a beat (called end-systolic volume) from the volume of blood just prior to the beat (called end-diastolic volume). Change from baseline in left ventricular volume was reported using modified Simpson's technique.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Left Ventricular Wall Thickness
Left ventricle is the chamber in the heart responsible for pumping blood to the rest of the body. Thickening of the lower chambers of left ventricular wall is also termed as ventricular hypertrophy. It was assessed by echocardiography using 2-dimensional gray-scale imaging; M-mode.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Left Ventricular Geometry
Left ventricular geometry was assessed by echocardiography using 2-dimensional gray-scale imaging. Relative wall thickness was the index of left ventricular geometry and defined as the sum of interventricular septal thickness (mm) and posterior wall thickness (mm) divided by LV internal end-diastolic diameter (mm).
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Right Ventricular Dimension
Right ventricle is the chamber in the heart responsible for pumping blood to the lungs. Right ventricular dimensions included end-diastole area (EDA) and end-systole area (ESA). It was assessed by echocardiography using 2-dimensional gray-scale imaging.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Right Ventricular Dimension
Right ventricle is the chamber in the heart responsible for pumping blood to the lungs. Right ventricular dimensions included end-diastole area and end-systole area. It was assessed by echocardiography using 2-dimensional gray-scale imaging. Change from baseline in right ventricular dimension was reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Atrial Volume
Atrial volumes were assessed by echocardiography using 2-dimensional gray-scale imaging and were calculated using the bi-plane area-length method. Both end-systole volumes (ESV) and end-diastole volumes (EDV) were reported.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Atrial Volumes
Atrial volumes were assessed by echocardiography using 2-dimensional gray-scale imaging and were calculated using the bi-plane area-length method. Both end-systole volumes and end-diastole volumes were reported. Change from baseline in atrial volume was reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Ejection Fraction
Systolic ejection fraction was the fraction of the end-diastolic volume (EDV) that was ejected out of left ventricle with each contraction, estimated by echocardiography. EDV was the volume of blood within a ventricle immediately before a contraction. Ejection fraction served as a general measure of the cardiac function of a participant.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Ejection Fraction
Systolic ejection fraction was the fraction of the end-diastolic volume that was ejected out of left ventricle with each contraction, estimated by echocardiography. EDV was the volume of blood within a ventricle immediately before a contraction. Ejection fraction served as a general measure of the cardiac function of a participant. Change from baseline in ejection fraction was reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Peak Contractile Velocity
It was assessed by echocardiography using Tissue Doppler Imaging (Color Post-Processing).
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Peak Contractile Velocity
It was assessed by echocardiography using Tissue Doppler Imaging (Color Post-Processing). Change from baseline in peak contractile velocity was reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Rotation/Torsion
Torsion is the twisting of an object due to an applied torque. It is expressed in newton metres. The left ventricle twists in systole storing potential energy and untwists (recoils) in diastole releasing the energy. Twist aids left ventricular ejection and untwist aids relaxation and ventricular filling. Therefore, rotation and torsion are important in cardiac mechanics. It was assessed by echocardiography using speckled tracking analysis .
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Global Strain Rate
Global longitudinal left ventricular strain rate was defined as the rate of percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global strain rate was assessed by echocardiography using speckled tracking analysis.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes
Change From Baseline in Systolic Global Strain Rate
Global longitudinal left ventricular strain rate was defined as the rate of percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global strain rate was assessed by echocardiography using speckled tracking analysis. Change from baseline in systolic global strain rate was reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Trans-mitral Doppler: Ratio
Trans-mitral doppler ratio was Transmitral E wave peak velocity divided by transmitral A wave peak velocity. The E/A ratio was defined the ratio of the early (E) to late (A) ventricular filling velocities and was marker of the function of the left ventricle of the heart. It was determined on spectral doppler echocardiography.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes
Change From Baseline in Trans-mitral Doppler Ratio
Trans-mitral doppler ratio was Transmitral E wave peak velocity divided by transmitral A wave peak velocity. The E/A ratio was defined the ratio of the early (E) to late (A) ventricular filling velocities and was marker of the function of the left ventricle of the heart. It was determined on spectral doppler echocardiography. Change from baseline in trans-mitral ration was reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Trans-mitral Doppler: Time
Trans-mitral doppler time was measured as the time between the closure of the aortic valve and the opening of the mitral valve. It was determined on spectral doppler echocardiography.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Trans-mitral Doppler Time
Trans-mitral doppler time was measured as the time between the closure of the aortic valve and the opening of the mitral valve. It was determined on spectral doppler echocardiography. Change from baseline in trans-mitral doppler time was reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Early and Late Peak Tissue Velocity
Tissue velocities were measured off-line from two dimensional (2D) color-coded tissue doppler images and reported as the average of 3 consecutive cardiac cycles. Tissue Doppler Imaging measured the velocity of the heart muscle or myocardium through the phases of one or more heartbeats by the Doppler effect (frequency shift) of the reflected ultrasound. Early and late peak tissue velocities (EPV and LPV) were reported.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Early and Late Peak Velocity
Tissue velocities were measured off-line from 2D color-coded tissue doppler images and reported as the average of 3 consecutive cardiac cycles. Tissue Doppler Imaging measured the velocity of the heart muscle or myocardium through the phases of one or more heartbeats by the Doppler effect (frequency shift) of the reflected ultrasound. Change from baseline in early and late peak tissue velocities were reported.
Measured: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Diastolic Strain Rate
Diastolic strain rate was defined as the rate of percent change in all segments of left ventricular dimension in comparison to its original dimension. It was assessed by echocardiography using speckled tracking analysis.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Peak Diastolic Untwisting Rate
Diastolic untwisting is an important component of early diastolic left ventricular filling. Left ventricular diastolic function is determined by early diastolic relaxation and myocardial stiffness. Peak diastolic untwisting rate is defined as the rate of left ventricular relaxation. It was assessed by echocardiography using speckled tracking analysis.
Measured: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Plasma Metabolomic Profiles Before and Immediately Following Steady State and Incremental Exercise
Plasma metabolomic profiles before and immediately following steady state and incremental exercise were collected using vacutainer tube containing dipotassium ethylenediamine tetraacetic Acid (K2EDTA) were processed by the clinical site according to handling specifications.
Measured: 1 hour pre-dose, 1 hour 20 minutes and 2 hours 10 minutes post-dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2013 (estimated)
- Study startApr 2013
- Primary completionOct 2013
- Study completionOct 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01819922
- Sponsor's protocol ID
- B1731008
- Status last verified
- Mar 2016
- First submitted
- 24 Feb 2013
- Last updated
- 2 May 2016
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 May 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1 Randomized, Double-blind, Placebo-controlled, Two-way Crossover Study To Assess The Effect Of Pf-05175157 As A Single Oral Dose On Metabolic And Cardiopulmonary Parameters During Steady State And Graded Exercise In Healthy Subjects
- ClinicalTrials.gov ID
- NCT01819922
- Acronym / sponsor ID
- B1731008
- Conditions
- Healthy
- Keywords
- Cardiopulmonary exercise testing, metabolic parameters, Diabetes Mellitus Type 2
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Apr 2013
- Primary completion
- Oct 2013 (actual)
- Study completion
- Oct 2013 (actual)
- First posted
- 28 Mar 2013 (estimated)
- Results
- Posted 2 May 2016
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to assess the effect of one single dose of PF-05175157 on metabolic and cardiopulmonary parameters before, during and after treadmill exercise in healthy volunteers.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PF-05175157 | Experimental | Drug: PF-05175157 |
| Placebo | Placebo comparator | Drug: Placebo |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Healthy male and/or female subjects of non child bearing potential only, between the ages of 18 and 40 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
- Body Mass Index (BMI) of 18 to 28 kg/m2; and a total body weight >50 kg (110 lbs).
- Subjects with maximum effort studies (peak RER >1.05) and normal exercise capacity as defined by peak VO2 ≥80% and ≤120% of predicted and no evidence of inducible ischemia or significant arrhythmia at the time of peak aerobic capacity testing 3 (±1) days prior to initiation of the study.
Key exclusion criteria (3 listed)
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- History of smoking in the past 5 years or history or evidence of habitual use of other (non smoked) tobacco or nicotine-containing products within 3 months of Screening or positive cotinine test at Screening or Day -3 (±1).
- Dry eye symptoms
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PF-05175157600 mg as powder in capsule, one dose within 5 minutes prior to AM meal | Drug | PF-05175157 |
| PlaceboPlacebo powder in capsule, one dose within 5 minutes prior to AM meal | Drug | Placebo |
Primary outcome
Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 20 Minutes Pre-dose
Time frame: 20 minutes pre-dose
Global longitudinal left ventricular strain was defined as the percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global longitudinal LV strain was assessed by echocardiography using speckled tracking analysis.
Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 1 Hour 30 Minutes Post-dose
Time frame: 1 hour 30 minutes post-dose
Global longitudinal left ventricular strain was defined as the percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global longitudinal LV strain was assessed by echocardiography using speckled tracking analysis.
Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 2 Hours 5 Minutes Post-dose
Time frame: 2 hours 5 minutes post-dose
Global longitudinal left ventricular strain was defined as the percent change in left ventricular longitudinal dimension in comparison to its original dimension. Global longitudinal LV strain was assessed by echocardiography using speckled tracking analysis.
Cardiopulmonary Exercise Test: Oxygen Uptake Efficiency Slope (OUES): 1 Hour 40 Minute Post-dose
Time frame: 1 hour 40 minutes post-dose
OUES was defined as an index of cardiopulmonary functional reserve that was based upon a submaximal exercise effort. OUES relates oxygen uptake to total ventilation during exercise.
36 secondary outcomes
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to 5-10 days after last dose of study drug (up to 25 days)
Number of Participants With Clinically Significant Laboratory Abnormalities
Time frame: Baseline up-to 3 hours post-dose
Number of Participants With Categorical Post-dose Cardiovascular Monitoring Data
Time frame: Baseline up-to 3 hours post-dose
Number of Participants With Categorical Post-dose Cardiovascular Monitoring Data: Electrocardiogram (ECG) Parameters
Time frame: Baseline up-to 3 hour post-dose
Cardiopulmonary Exercise Test: Peak Volume of Oxygen (VO2)
Time frame: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Respiratory Exchange Ratio (RER)
Time frame: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Minute Ventilation and Carbon Dioxide Production (VE/VCO2 Slope)
Time frame: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Volume of Oxygen (VO2) at Anaerobic Threshold (AT)
Time frame: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Oxygen (O2) Pulse
Time frame: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Oxygen (O2) Kinetics
Time frame: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Aerobic Efficiency
Time frame: 1 hour 40 minutes post-dose
Cardiopulmonary Exercise Test: Physical Work Capacity at a Heart Rate of 130 Beats Per Minute (PWC 130)
Time frame: 1 hour 40 minutes post-dose
Cardiac Structure: Left Ventricular Volume
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in the Left Ventricular Volume
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Left Ventricular Wall Thickness
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Left Ventricular Geometry
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Right Ventricular Dimension
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Right Ventricular Dimension
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Cardiac Structure: Atrial Volume
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Atrial Volumes
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Ejection Fraction
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Ejection Fraction
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Peak Contractile Velocity
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Peak Contractile Velocity
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Rotation/Torsion
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Systolic Function: Global Strain Rate
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes
Change From Baseline in Systolic Global Strain Rate
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Trans-mitral Doppler: Ratio
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes
Change From Baseline in Trans-mitral Doppler Ratio
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Trans-mitral Doppler: Time
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Trans-mitral Doppler Time
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Early and Late Peak Tissue Velocity
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Change From Baseline in Early and Late Peak Velocity
Time frame: 1 hour 30 minutes and 2 hours 5 minutes post-dose
Diastolic Strain Rate
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Peak Diastolic Untwisting Rate
Time frame: 20 minutes pre-dose, 1 hour 30 minutes and 2 hours 5 minutes post-dose
Plasma Metabolomic Profiles Before and Immediately Following Steady State and Incremental Exercise
Time frame: 1 hour pre-dose, 1 hour 20 minutes and 2 hours 10 minutes post-dose
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 May 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing PF-05175157 in people with Healthy, run by Pfizer at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 May 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 May 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Systolic Function: Global Longitudinal Left Ventricular (LV) Strain: 20 Minutes Pre-dose (time frame: 20 minutes pre-dose). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2016.